These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15900623)

  • 1. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.
    Moss AJ
    Circulation; 2005 May; 111(19):2537-49; discussion 2537-49. PubMed ID: 15900623
    [No Abstract]   [Full Text] [Related]  

  • 2. Should everyone with an ejection fraction less than or equal to 30% receive an implantable cardioverter-defibrillator? Not everyone with an ejection fraction < or = 30% should receive an implantable cardioverter-defibrillator.
    Buxton AE
    Circulation; 2005 May; 111(19):2537-49; discussion 2537-49. PubMed ID: 15897357
    [No Abstract]   [Full Text] [Related]  

  • 3. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation?
    Armoundas AA; Hohnloser SH; Ikeda T; Cohen RJ
    Nat Clin Pract Cardiovasc Med; 2005 Oct; 2(10):522-8. PubMed ID: 16186850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk stratification for sudden death in heart failure.
    Farwell D; Gollob MH
    Minerva Cardioangiol; 2007 Jun; 55(3):379-84. PubMed ID: 17534256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Risk stratification for sudden cardiac death: should we juist consider ejection fraction?].
    Paolucci M; Cattafi G; Magenta G; Vecchi MR; Schirru M; Lunati M
    G Ital Cardiol (Rome); 2008 Oct; 9(10 Suppl 1):27S-32S. PubMed ID: 19195303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable cardioverter-defibrillator efficacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population).
    Zareba W; Piotrowicz K; McNitt S; Moss AJ;
    Am J Cardiol; 2005 Jun; 95(12):1487-91. PubMed ID: 15950580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria.
    Toma M; McAlister FA; Ezekowitz J; Kimber S; Gulamhusein S; Pantano A; Sivakumaran S; Cujec B; Paterson I; Armstrong PW
    Am J Cardiol; 2006 Mar; 97(6):882-5. PubMed ID: 16516594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biventricular pacing and defibrillator use in chronic heart failure.
    Cesario DA; Turner JW; Dec GW
    Cardiol Clin; 2007 Nov; 25(4):595-603; vii. PubMed ID: 18063163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moderate exercise training improves functional capacity, quality of life, and endothelium-dependent vasodilation in chronic heart failure patients with implantable cardioverter defibrillators and cardiac resynchronization therapy.
    Belardinelli R; Capestro F; Misiani A; Scipione P; Georgiou D
    Eur J Cardiovasc Prev Rehabil; 2006 Oct; 13(5):818-25. PubMed ID: 17001224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator.
    Silka MJ; Bar-Cohen Y
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):298-306. PubMed ID: 19808422
    [No Abstract]   [Full Text] [Related]  

  • 13. Statins reduce appropriate cardioverter-defibrillator shocks and mortality in patients with heart failure and combined cardiac resynchronization and implantable cardioverter-defibrillator therapy.
    Desai H; Aronow WS; Tsai FS; Ahn C; Lai HM; Amin H; Gandhi K; Frishman WH; Cohen M; Sorbera C
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):176-9. PubMed ID: 19617418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Implantable cardioverter defibrillator implantation guidelines based solely on left ventricular ejection fraction do not apply to adults with congenital heart disease.
    Triedman JK
    Circ Arrhythm Electrophysiol; 2008 Oct; 1(4):307-16; discussion 316. PubMed ID: 19808423
    [No Abstract]   [Full Text] [Related]  

  • 15. Competing risk analysis of cause-specific mortality in patients with an implantable cardioverter-defibrillator: The EVADEF cohort study.
    Marijon E; Trinquart L; Otmani A; Waintraub X; Kacet S; Clémenty J; Chatellier G; Le Heuzey JY;
    Am Heart J; 2009 Feb; 157(2):391-397.e1. PubMed ID: 19185651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of death: implantable cardioverter defibrillators and proactive care.
    Sears SF; Sowell LV; Kuhl EA; Handberg EM; Kron J; Aranda JM; Conti JB
    Pacing Clin Electrophysiol; 2006 Jun; 29(6):637-42. PubMed ID: 16784431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter-defibrillator therapy in clinical practice.
    Cesario DA; Dec GW
    J Am Coll Cardiol; 2006 Apr; 47(8):1507-17. PubMed ID: 16630984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?
    Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton AE; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders GD
    Int J Cardiol; 2014 Mar; 172(1):253-4. PubMed ID: 24467982
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanisms of sudden cardiac death in myocardial infarction survivors: insights from the randomized trials of implantable cardioverter-defibrillators.
    Bunch TJ; Hohnloser SH; Gersh BJ
    Circulation; 2007 May; 115(18):2451-7. PubMed ID: 17485594
    [No Abstract]   [Full Text] [Related]  

  • 20. Utility of microvolt T-wave alternans to predict sudden cardiac death in patients with cardiomyopathy.
    Chauhan VS; Selvaraj RJ
    Curr Opin Cardiol; 2007 Jan; 22(1):25-32. PubMed ID: 17143041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.